Study finds HFCWO Therapy using Philips InCourage System reduces hospitalizations
July 23 2020 - 9:00AM
July 23, 2020
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG,
AEX: PHIA), a global leader in health technology, today announced
the publication of a peer-reviewed, retrospective outcomes study
demonstrating that, in the first year of use, high frequency chest
wall oscillation therapy (HFCWO) using the Philips InCourage System
reduced the rate of chronic respiratory patient hospitalization by
more than 50 percent. According to the study, antibiotic use also
decreased significantly. The study examined data from a registry of
adult bronchiectasis patients’ self-reported outcomes collected by
RespirTech, a Philips company. This data repository is now the
largest bronchiectasis research registry in the world.
According to the American Lung Association, nearly 37 million
U.S. adults live with a chronic respiratory disease, including
cystic fibrosis, chronic obstructive pulmonary disease (COPD), and
bronchiectasis [1]. Exacerbations of these chronic respiratory
diseases can be a major source of costs for healthcare systems and
insurers, as hospitalizations and readmissions result in billions
of dollars of additional healthcare costs each year. Such
exacerbations have a negative impact on quality of life, as
patients experiencing numerous episodes report symptoms such as low
energy, shortness of breath, and excess mucus production. This
study observed chronic respiratory patients receiving HFCWO
therapy, an airway clearance technique that uses a fitted vest to
apply external chest wall oscillations in an attempt to combat
these issues.
The study, “Real-life experience with high-frequency chest wall
oscillation vest therapy in adults with non-cystic fibrosis
bronchiectasis” [2], found that initiating airway clearance with
non-invasive HFCWO therapy is associated with keeping patients out
of the hospital, reducing their need for medications, and improving
quality of life. It is the largest study of airway clearance use
for bronchiectasis to date. After monitoring 2,596 patients using
Philips InCourage System, the study concluded that in the first
year of vest use, the rate of hospitalization dropped 54.5%,
self-reported ability to clear lungs improved from 13.9% to 76.6%,
and antibiotic use dropped from 57.7% to 29.9%. As an added
benefit beyond the results of the study, the Philips InCourage
System is uniquely supported by patient-centric services designed
to optimize product use, improve patient-provider communication,
and encourage therapy adherence.
“Chronic respiratory conditions, like bronchiectasis and COPD,
contribute to significant healthcare costs each year between
hospitalizations and readmissions. Now, more than ever, health
systems and insurers are looking for ways to mitigate these costs,
while also balancing quality care,” said Gary Hansen, Director of
Scientific Affairs with RespirTech, a Philips Company. “This study
shows positive results that HFCWO therapy delivered by the
InCourage system, coupled with RespirTech’s patient-centered
service model, can help to reduce hospitalizations and antibiotic
use for chronic respiratory patients, while also improving their
overall quality of life.”
According to William S., a participant in the study, “I couldn’t
walk across the room, take a shower or get dressed without losing
my breath before I used this system. I [now] use the system three
times a day for 30 minutes. [It has] eliminated the need for
antibiotics for constant lung infections. It has been 1.5 years
since my last lung infection. It used to be every two months.”
[3]
In 2017, Philips acquired Minnesota-based RespirTech to
complement and expand Philips Respiratory Care solution portfolio.
To learn more about Philips InCourage system and airway clearance
solutions including RespirTech patient services, please visit
www.RespirTech.com.
[1] American Lung Association,
https://www.lung.org/about-us/mission-impact-and-history/our-impact#:~:text=Improving%20Quality%20of%20Life%20for,includes%20emphysema%20and%20chronic%20bronchitis.[2]
Barto, et. al, “Real-life experience with high-frequency chest wall
oscillation vest therapy in adults with non-cystic fibrosis
bronchiectasis.” Therapeutic Advances in Respiratory Disease, vol
14, June 15, 2020,
https://journals.sagepub.com/doi/full/10.1177/1753466620932508.
Barto is a consultant for RespirTech. Daignault and Hansen are
employees of RespirTech. [3] Individual results may vary
For further information, please contact:
Meredith Amoroso Philips Global Press Office Tel:
+1-724-584-8991E-mail: meredith.amoroso@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found
at www.philips.com/newscenter.
- InCourage Patient Playing Games
- Philips InCourage vest
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2023 to Apr 2024